Neal C. Bradsher - Jul 1, 2024 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director, 10%+ Owner
Signature
Neal C. Bradsher, /s/ Neal C. Bradsher
Stock symbol
LCTX
Transactions as of
Jul 1, 2024
Transactions value $
$0
Form type
4
Date filed
7/3/2024, 02:00 PM
Previous filing
Jul 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX OPTION TO PURCHASE COMMON SHARES Award $0 +75K $0.00 75K Jul 1, 2024 COMMON SHARES 75K $0.95 Direct F1, F2
holding LCTX OPTION TO PURCHASE COMMON SHARES 50K Jul 1, 2024 COMMON SHARES 50K $1.41 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 50K Jul 1, 2024 COMMON SHARES 50K $1.57 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 50K Jul 1, 2024 COMMON SHARES 50K $2.86 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 40K Jul 1, 2024 COMMON SHARES 40K $0.83 Direct F3
holding LCTX OPTION TO PURCHASE COMMON SHARES 40K Jul 1, 2024 COMMON SHARES 40K $1.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options will vest and become exercisable on July 1, 2025, provided, that Neal C. Bradsher (the "Reporting Person") remains a member of the board of directors of Lineage Cell Therapeutics, Inc. (the "Issuer") on that date.
F2 These options were granted to the Reporting Person by the Issuer on July 1, 2024 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
F3 These options are currently exercisable.